Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.68 Million CAD | -13.26% |
| 2022 | -2.86 Million CAD | -93.14% |
| 2021 | -1.22 Million CAD | -294.77% |
| 2020 | -314.79 Thousand CAD | 83.65% |
| 2019 | -2.37 Million CAD | 27.48% |
| 2018 | -2.61 Million CAD | 30.03% |
| 2017 | -3.69 Million CAD | 20.17% |
| 2016 | -4.69 Million CAD | 6.45% |
| 2015 | -4.96 Million CAD | -97.18% |
| 2014 | -2.54 Million CAD | -54.88% |
| 2013 | -1.64 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -577.46 Thousand CAD | 9.09% |
| 2024 Q2 | -660.25 Thousand CAD | -2.13% |
| 2023 Q1 | -680.15 Thousand CAD | -74.34% |
| 2023 Q2 | -633.31 Thousand CAD | 6.89% |
| 2023 Q4 | -631.48 Thousand CAD | 14.34% |
| 2023 Q3 | -737.18 Thousand CAD | -16.4% |
| 2023 FY | - CAD | -13.26% |
| 2022 Q4 | -390.12 Thousand CAD | 19.38% |
| 2022 Q2 | -702.6 Thousand CAD | 8.71% |
| 2022 Q1 | -769.66 Thousand CAD | -301.82% |
| 2022 FY | - CAD | -93.14% |
| 2022 Q3 | -483.92 Thousand CAD | 31.12% |
| 2021 Q2 | -345.46 Thousand CAD | 25.61% |
| 2021 Q4 | -191.54 Thousand CAD | 14.77% |
| 2021 FY | - CAD | -294.77% |
| 2021 Q1 | -464.4 Thousand CAD | -261.47% |
| 2021 Q3 | -224.74 Thousand CAD | 34.94% |
| 2020 FY | - CAD | 83.65% |
| 2020 Q3 | -38.14 Thousand CAD | -255.69% |
| 2020 Q2 | 24.49 Thousand CAD | 114.54% |
| 2020 Q1 | -168.48 Thousand CAD | 37.97% |
| 2020 Q4 | -128.47 Thousand CAD | -236.83% |
| 2019 Q2 | -556.75 Thousand CAD | 15.01% |
| 2019 FY | - CAD | 27.48% |
| 2019 Q3 | -459.51 Thousand CAD | 17.47% |
| 2019 Q1 | -655.11 Thousand CAD | -5.67% |
| 2019 Q4 | -271.6 Thousand CAD | 40.89% |
| 2018 Q4 | -619.95 Thousand CAD | -1.93% |
| 2018 FY | - CAD | 30.03% |
| 2018 Q2 | -622.4 Thousand CAD | 19.02% |
| 2018 Q3 | -608.21 Thousand CAD | 2.28% |
| 2018 Q1 | -768.63 Thousand CAD | -30.38% |
| 2017 Q1 | -967.86 Thousand CAD | 15.45% |
| 2017 FY | - CAD | 20.17% |
| 2017 Q4 | -589.51 Thousand CAD | 36.81% |
| 2017 Q3 | -932.96 Thousand CAD | 34.88% |
| 2017 Q2 | -1.43 Million CAD | -48.02% |
| 2016 Q1 | -1.12 Million CAD | 14.53% |
| 2016 FY | - CAD | 6.45% |
| 2016 Q2 | -1.34 Million CAD | -19.24% |
| 2016 Q4 | -1.14 Million CAD | -6.39% |
| 2016 Q3 | -1.07 Million CAD | 19.85% |
| 2015 Q1 | -1.09 Million CAD | 20.31% |
| 2015 Q4 | -1.31 Million CAD | 7.77% |
| 2015 FY | - CAD | -97.18% |
| 2015 Q3 | -1.42 Million CAD | -22.5% |
| 2015 Q2 | -1.16 Million CAD | -6.27% |
| 2014 Q4 | -1.37 Million CAD | -175.64% |
| 2014 FY | - CAD | -54.88% |
| 2014 Q3 | -499.46 Thousand CAD | -26.88% |
| 2014 Q1 | -272.11 Thousand CAD | 15.18% |
| 2014 Q2 | -393.66 Thousand CAD | -44.67% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | -320.79 Thousand CAD | -23.96% |
| 2013 Q3 | -258.78 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CanadaBis Capital Inc. | 5.67 Million CAD | 147.225% |
| Decibel Cannabis Company Inc. | 5.67 Million CAD | 147.216% |
| Delivra Health Brands Inc. | 2.35 Million CAD | 213.907% |
| Entourage Health Corp. | -21.39 Million CAD | 87.468% |
| Lifeist Wellness Inc. | -12.76 Million CAD | 79.002% |
| Cannara Biotech Inc. | 17.18 Million CAD | 115.601% |
| Medicure Inc. | 1.27 Million CAD | 310.635% |
| PharmaCielo Ltd. | -12.01 Million CAD | 77.69% |
| Rubicon Organics Inc. | 1.94 Million CAD | 237.648% |
| BioSyent Inc. | 9.05 Million CAD | 129.604% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | -119.614% |